Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma.

Conclusions: Our study emphasizes the importance of immunomodulation in EAC marking IDO as a potential biomarker. Beyond this, IDO might indicate a subgroup of EAC with an explicit survival benefit.
PMID: 33029538 [PubMed - in process]

Source: Journal of Immunology Research - October 9, 2020 Category: Allergy & Immunology Tags: J Immunol Res Source Type: research